Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study

Abstract Hormone receptor (HR) positive (HR +) and human epidermal growth factor receptor 2 (HER2) negative (aka HER2 −) breast cancer (BC) is the most frequently diagnosed subtype. Recent development of next-generation endocrine therapies (e.g. selective estrogen receptor degraders (SERDs); third-g...

詳細記述

書誌詳細

出版年:	BMC Cancer
主要な著者:	Grazia Arpino, Carmine De Angelis, Lorenzo Gerratana, Matteo Lambertini, Sarah Igidbashian, Rosanna Gramigna, Xavier Guillaume
フォーマット:	論文
言語:	英語
出版事項:	BMC 2025-05-01
主題:	Adverse events Metastatic HR positive/HER2 negative breast cancer Stakeholder preferences Treatment administration Treatment choice
オンライン･アクセス:	https://doi.org/10.1186/s12885-025-14308-4